Skip to main content
Download PDF

Oxidative stress in patients with coronavirus disease and end-stage renal disease: a pilot study

BMC Nephrology volume 25, Article number: 155 (2024) Cite this article

Abstract

Background

Oxidative stress, an imbalance between reactive oxygen species production and antioxidant capacity, increases in patients with coronavirus disease (COVID-19) or renal impairment. We investigated whether combined COVID-19 and end-stage renal disease (ESRD) would increase oxidative stress levels compared to each disease alone.

Methods

Oxidative stress was compared among three groups. Two groups comprised patients with COVID-19 referred to the hospital with or without renal impairment (COVID-ESRD group [n = 18]; COVID group [n = 17]). The third group (ESRD group [n = 18]) comprised patients without COVID-19 on maintenance hemodialysis at a hospital.

Results

The total oxidative stress in the COVID-ESRD group was lower than in the COVID group (p = 0.047). The total antioxidant status was higher in the COVID-ESRD group than in the ESRD (p < 0.001) and COVID (p < 0.001) groups after controlling for covariates. The oxidative stress index was lower in the COVID-ESRD group than in the ESRD (p = 0.001) and COVID (p < 0.001) groups. However, the three oxidative parameters did not differ significantly between the COVID and COVID-ESRD groups.

Conclusions

The role of reactive oxygen species in the pathophysiology of COVID-19 among patients withESRD appears to be non-critical. Therefore, the provision of supplemental antioxidants may not confer a therapeutic advantage, particularly in cases of mild COVID-19 in ESRD patients receiving hemodialysis. Nonetheless, this area merits further research.

Peer Review reports

Background

Diatomic oxygen can form highly reactive chemicals called reactive oxygen species (ROS), which include peroxide, superoxide, hydroxyl radical, and singlet oxygen [1]. ROS have a pathophysiologic role in regulating various cellular responses through signal transduction [2]. Generally, low levels of ROS activate pathways that promote cell survival, while high levels of ROS activate pathways that induce cell death, such as apoptosis and necrosis [3]. Mammalian cells have antioxidant enzymes to maintain the cellular redox balance,including superoxide dismutase, catalase, glutathione reductase, and peroxidase [4]. They also have non-enzyme antioxidants, such as glutathione, thioredoxin, sulfa-containing amino acids, uric acid, ascorbic acid, and vitamin E in vivo [4].

Oxidative stress (OS), the imbalance between ROS production and antioxidant capacity, is increased in patients with renal impairment due to increased oxidant activity and reduced antioxidant capacity, which worsens with renal dysfunction [5]. A source of oxidative stress in patients with end-stage renal disease (ESRD) is the uremic toxins that trigger inflammation by activating polymorph nuclear cells, IL-1β, and IL-8 [6]. Moreover, hemodialysis (HD) increases OS due to the loss of antioxidants during dialysis and the activation of white blood cells, which generate ROS [7]. OS is higher in patients with coronavirus disease (COVID-19) than in healthy individuals [8] and higher in patients with more severe forms of COVID-19 than those with mild ones or healthy controls [9].

Patients with COVID-19 and ESRD undergoing HD have a markedly increased risk of mortality and morbidity from all causes [10]. Based on this evidence, we hypothesized that combining COVID-19 and ESRD may enhance OS more than COVID-19 with normal renal function or ESRD without COVID-19.A study might be structured to validate this hypothesis by comparing the OS levels among patients with ESRD with or without COVID-19 and patients with COVID-19 without ESRD, with statistical control of potential internal confounding factors. However, few studies are available to measure oxidative stress among COVID-19 patients with ESRD, which is more valid for those employing Total oxidative stress (TOS) and total antioxidant status (TAS) assays for analysis. Thus, an independent pilot study with a small sample size was designed for preliminary data before a potential main study to validate the hypothesis.

Methods

Study design and participants

The study was conducted at Chung-Ang Jeil Hospital (CAJH), a secondary hospital in Jincheon County, Chungbuk Province, South Korea, and the surrounding areas, with a population of approximately 200,000.Since the World Health Organization declared COVID-19 a pandemic on January 30, 2020, South Korea has implemented an active surveillance system that works closely with private healthcare facilities. The system required all individuals with COVID-19 symptoms or epidemiological links to be tested for COVID-19. All confirmed patients with COVID-19 with ESRD on HD were sent to designated health facilities for proper medical care and isolated maintenance of HD.

Between December 21, 2021, and June 30, 2023, 1058 patients with COVID-19 (aged ≥ 18 years, males: 509, females: 549) were referred to CAJH by the Provincial Ministry of Public Health. The diagnosis of COVID-19 was based on nasopharyngeal swab positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by polymerase chain reaction or rapid antigen testing for suspected cases that met the World Health Organization clinical criteria or had epidemiological links. Of the 1058 patients with COVID-19, 120 underwent ESRD-demanding HD.

Three groups were identified for the study. The COVID group (n = 17) comprised patients with confirmed COVID-19 but with normal renal function (estimated glomerular filtration rate > 60 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, 2021). The ESRD group (n = 18) comprised patients who regularly underwent HD at the CAJH for > sixmonths without evidence of SARS-CoV-2 infection. Patients with a previous SARS-CoV-2 infection within six months were excluded from this study.

In the context of a pilot study with sample sizes approximating 20 [11, 12], the recruitment strategy entailed disseminating study information to every 15th COVID-19 patient exhibiting normal renal function and every 7th patient with ESRD. Of these, 17 individuals in the COVID group and 18 in the COVID-ESRD group consented to partake in the research, providing written informed consent. Additionally, 18 ESRD patients undergoing hemodialysis (HD) at CAJH with no prior COVID-19 infection were randomly selected to participate.

Ethical considerations

This study was approved by the Public Institutional Review Board of the Ministry of Health and Welfare of South Korea (http://irb.or.kr/menu02/summary.aspx, approval no: P01-202308–01-030). It was conducted using the principles of the Declaration of Helsinki. Written informed consent was obtained from all the participants.

Assay

Total oxidative stress (TOS) and total antioxidant status (TAS) assays were outsourced to EONE Laboratories (Incheon, South Korea: https://www.eonelab.co.kr/institution/certi_list.asp). The commercial assay kits of TOS and TAS were from Rel Assay Diagnostics, Dusseldorf, Germany (https://www.relassay.com/products). The principles of the assay for TOS and TAS are as follows:

Measurement of TOS

Oxidants in the sample oxidize the ferrous ion-chelator complex to ferric ion, which forms a colored complex with chromogen in an acidic medium. The color intensity, which can be measured spectrophotometrically, is related to the sample's total amount of oxidant molecules. The assay is calibrated with hydrogen peroxide, and the results are expressed in terms of micromolar hydrogen peroxide equivalent per liter (μmolH2O2 Eq./L).

Measurement of TAS

The Fenton reaction generates the hydroxyl radical that reacts with the colorless substrate O-dianisidine to produce the dianisyl radical, which has a bright yellowish-brown color. Upon adding a plasma sample, the oxidative reactions triggered by the hydroxyl radicals present in the reaction mix are suppressed by the antioxidant components of the plasma. This suppression prevents color change, thereby providing an adequate measure of the total antioxidant capacity of the plasma. The assay results are expressed as mmol Trolox Eq./L.

The oxidativestress index (OSI) was calculated from the following equation:

$$\mathrm{OSI}=TOS\left(\mu mol {\mathrm H}_2{\mathrm O}_2 Equiv./L\right)/\left(TAS\times10\right)\left(mmol Trolox Equiv./L\right).$$

Data collection

After reviewing the electronic medical records, data for the following variables were collected: age, sex, body mass index (BMI), and comorbidities of diabetes mellitus.

Statistical analyses

Categorical variables were expressed using frequencies and percentages, while continuous variables were described using means and standard deviations. The chi-squared test was used for categorical variables to investigate the significant difference among the three groups.

Analysis of covariance (ANCOVA) was conducted to examine the group mean differences while controlling for covariates that affect oxidative stress, including age, gender, obesity, and diabetes [13,14,15,16]. Transformations were applied to TOS, TAS, and OSI due to their non-normal distribution and lack of homoscedasticity,precisely, logarithmic transformations for TAS and OSI and a square root transformation for TOS. The Shapiro–Wilk and Levene's tests confirmed the normal distribution and homogeneity of variances of the residuals, respectively [17, 18]. Following these transformations, ANCOVA was reapplied to assess the mean differences between the COVID-ESRD, COVID, and ESRD groups, adjusted for the covariates. A post-hoc Tukey's Honestly Significant Difference (HSD) test was then performed for in-depth pairwise group comparisons [19].

Statistical significance was defined as a two-sided p-value of < 0.05. All statistical analyses were conducted using R Statistical Software (version 4.1.2).

Results

Demographic and clinical profiles of the patients are presented in Table 1. The prevalence of diabetes was higher among those with ESRD than those without, and the COVID group (47.7 ± 17.2 years) had a lower mean age than the ESRD (64.2 ± 16.1 years) and COVID-ESRD (62.7 ± 17.5 years) groups. However, the percentage of males and the mean BMI were not significantly different among the three groups (Table 1).

Table 1 Demographic and clinical profiles of the study participants
Full size table

Contrary to the hypothesis, the TOS level (μmolH2O2 Eq./L) in the COVID-ESRD group (3.24 ± 1.19) was lower than that in the COVID group (4.57 ± 2.09, p = 0.047;ANCOVA), while TAS (mmol Trolox Eq./L) showed significantly higher levels in the COVID-ESRD group (2.29 ± 0.49) than inthe ESRD (1.74 ± 0.33, p < 0.001;ANCOVA) and COVID (1.52 ± 0.23, p < 0.001;ANCOVA) groups after controlling the covariates including age, gender, comorbidities (diabetes), and BMI. Meanwhile, OSI (TOS/TAS × 10) was significantly lower in the COVID-ESRD group (0.14 ± 0.05) than in the ESRD (0.26 ± 0.10, p = 0.001;ANCOVA) and COVID (0.31 ± 0.16, p < 0.001;ANCOVA) groups. However, the three oxidative parameters (TOS, TAS, and OSI) did not differ statistically between the COVID and the ESRD groups (Table 2, Fig. 1).

Table 2 Oxidative values in the three study groups
Full size table
Fig. 1
figure 1

Oxidative stress parameters of the study groups. Oxidative stress index \(\mathrm{OSI}=TOS\left(\mu mol{\mathrm H}_2{\mathrm O}_2\mathrm{Equiv}./\mathrm L\right)/\left(TASx\;10\right)\left(mmolTroloxEquiv./L\right)\). Abbreviations: COVID-ESRD, patients with coronavirus disease (COVID-19) with end-stage renal disease; COVID, patients with COVID-19 with normal renal function; ESRD, patients with renal impairment without evidence of COVID-19; TOS, total oxidative stress; TAS, total antioxidant status; OSI, oxidative stress index. The asterisk (*) represents those with statistical significance according to the analysis of covariance

Full size image

Discussion

Oxidative stress markers, including TOS, are higher in COVID-19 cases than healthy individuals [8]. Patients with ESRD are also characterized by enhanced oxidative stress [20, 21]. Moreover, renal replacement therapy often accelerates prooxidant activity [7]. However, contrary to expectations, the present study showed that TOS was lower in the COVID-ESRD group than in the COVID group (Table 2, Fig. 1).

Uremia-induced immunosuppression, characterized by reduced synthesis of inflammatory cytokines following antigen stimulation [22] and B-cell lymphopenia in ESRD patients [23], may collectively serve as a suppressive mechanism against the generation of ROS. Given these, we cautiously hypothesize that within the uremic environment, the impaired immune response to COVID-19 could diminish stimulatory factors involved in ROS generation [24].

In general, for patients with ESRD, antioxidant status often deteriorates [25]. Altered dietary restrictions and preferences may exaggerate the depletion of antioxidant defense mechanisms, such as low levels of vitamins C and E, reduced selenium levels, decreased function of the glutathione scavenging system, and loss of vitamins during HD [26, 27]. However,the present study revealed a prominent increase in TAS in the COVID-ESRD group (Table 2, Fig. 1). Typically, exposure to pro-oxidants triggers the activation of antioxidant defense mechanisms. The activation of antioxidative enzymes may be attributed to decreased tACE2 levels upon viral entry into cells, alongside increased biologically active sACE2 levels due to heightened ADAM-17 activity [28, 29]. Augmented sACE2 may stimulate nuclear factor erythroid 2–related factor (Nrf2) [30], which in turn triggers the transcription of antioxidant genes such as superoxide dismutase, catalase, and glutathione peroxidase [31, 32].

Multiple factors may augment the antioxidative response in the COVID-ESRD group. Initially, the clinical severity observed in this study was predominantly mild, which contrasts with the cases reported in other researches. Evidence indicates a correlation between reduced antioxidant enzyme expression in patients with severe COVID-19 [33].

Furthermore, the pro-oxidant stress levels in this patient group might not have reached the threshold necessary to chelate antioxidants produced by the viral antigen. Additionally, it is noteworthy that, based on anecdotal evidence, a minority of the participants within the COVID-ESRD group might have commenced antioxidant therapy prior to their inclusion in the study, a detail that was not documented within the research parameters.Interestingly, a cross-sectional study also showed that serum total antioxidant capacity increased gradually along with the deterioration of renal function in patients with the stages of renal failure [34].

Oxidative stress is both a cause and a consequence of the pathophysiology of the infectious process [35]. In the early stages of viral infections, administering proinflammatory cytokines, which precede reactive ROS, can assist in managing the virus before adverse immune consequences manifest [36]. Considering that most COVID-19 cases within the COVID-ESRD group present with early-stage infection (mild to moderate), the attenuated oxidative stress observed may not contribute favorably to the prognosis of COVID-19 in individuals with renal dysfunction.

In a comprehensive, multinational, randomized clinical trial [37], the administration of vitamin C to hospitalized COVID-19 patients did not improve organ support-free days or hospital survival. Moreover, vitamin C was associated with a worsening of both outcomes in critically ill and non-critically ill patients. Considering that the sequence of physiological responses induced by oxidative stress could be a significant factor in the worsening of the host's condition [38], additional investigationis warranted for this unexpected findingin COVID-19 patients with ESRD.

This study has a few limitations. The primary challenge lies in quantifying oxidative stress within clinical medicine, given the intricate nature of the procedure and the several elements involved, encompassing both oxidants and antioxidants [39]. Although the statistical analysis was designed to control some internal factors affecting oxidative stress (age, sex, obesity, and comorbidities), the analysis has its inborn limitations caused by its small sample size. Furthermore, the study did not control for most external factors (physical activity, diet, medications, climate, etc.) affecting OS. Another limitation is the unavailability of control data in the general population, i.e., participants with normal renal function and without COVID-19 infection. Thus, a larger sample size requires further investigations with controlling internal and external confounding factors. Despite the limitations, this is the first study on oxidative stress parameters in patients with COVID-19 and ESRD on HD.

Conclusions

The role of reactive oxygen species in the pathophysiology of COVID-19 among patients withESRD appears to be non-critical. Therefore, the provision of supplemental antioxidants may not confer a therapeutic advantage, particularly in cases of mild COVID-19 in ESRD patients receiving hemodialysis. Nonetheless, this area merits further research.

Availability of data and materials

The data presented in this study are available on request from the corresponding author (syhong0526@gmail.com).

Abbreviations

ANCOVA:

Analysis of covariance

BMI:

Body mass index

CAJH:

Chung-Ang Jeil Hospital

COVID-19:

Coronavirus disease

ESRD:

End-stage renal disease

HD:

Hemodialysis

Nrf2:

Nuclear factor erythroid 2–related factor

OS:

Oxidative stress

OSI:

Oxidative stress index

ROS:

Reactive oxygen species

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2

TAS:

Total antioxidant status

TOS:

Total oxidative stress

References

  1. Oyama VI, Berdahl BJ, Woeller F, et al. The chemical activities of the Viking biology experiments and the arguments for the presence of superoxides, peroxides, gamma-Fe2O3 and carbon suboxide polymer in the Martian soil. Life Sci Space Res. 1978;16:3–8.

    Article  CAS  PubMed  Google Scholar 

  2. Wang Y, Branicky R, Noë A, et al. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol. 2018;217:1915–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yoon SO, Yun CH, Chung AS. Dose effect of oxidative stress on signal transduction in aging. Mech Ageing Dev. 2002;123:1597–604.

    Article  CAS  PubMed  Google Scholar 

  4. Helberg J, Pratt DA. Autoxidation vs. antioxidants - the fight for forever. Chem Soc Rev. 2021;50:7343–58.

    Article  CAS  PubMed  Google Scholar 

  5. Verma S, Singh P, Khurana S, et al. Implications of oxidative stress in chronic kidney disease: a review on current concepts and therapies. Kidney Res Clin Pract. 2021;40:183–93.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Pieniazek A, Bernasinska-Slomczewska J, Gwozdzinski L. Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD. Int J Mol Sci. 2021;22(12):6196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019;32:58–71.

    Article  PubMed  Google Scholar 

  8. Lage SL, Amaral EP, Hilligan KL, et al. Persistent Oxidative Stress and Inflammasome Activation in CD14(high)CD16(-) Monocytes From COVID-19 Patients. Front Immunol. 2021;12: 799558.

    Article  CAS  PubMed  Google Scholar 

  9. Passos FRS, Heimfarth L, Monteiro BS, et al. Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. Int Immunopharmacol. 2022;104: 108502.

    Article  PubMed  Google Scholar 

  10. Jdiaa SS, Mansour R, El Alayli A, et al. COVID-19 and chronic kidney disease: an updated overview of reviews. J Nephrol. 2022;35:69–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Browne RH. On the use of a pilot sample for sample size determination. Stat Med. 1995;14:1933–40.

    Article  CAS  PubMed  Google Scholar 

  12. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat J Appl Stat Pharm Ind. 2005;4:287–91.

    Google Scholar 

  13. Morris AA, Zhao L, Patel RS, et al. Differences in systemic oxidative stress based on race and the metabolic syndrome: the Morehouse and Emory Team up to Eliminate Health Disparities (META-Health) study. Metab Syndr Relat Disord. 2012;10:252–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kander MC, Cui Y, Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J Cell Mol Med. 2017;21:1024–32.

    Article  PubMed  Google Scholar 

  15. Janicki-Deverts D, Cohen S, Matthews KA, et al. Socioeconomic status, antioxidant micronutrients, and correlates of oxidative damage: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Psychosom Med. 2009;71:541–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol. 2004;122:333–8.

    Article  CAS  PubMed  Google Scholar 

  17. Shapiro SS, Wilk MB. An Analysis of Variance Test for Normality (Complete Samples). Biometrika. 1965;52:591–611.

    Article  Google Scholar 

  18. Cleves M. Robust tests for the equality of variances. Stata Technical Bulletin 1996;5.

  19. Rutherford A. Anova and Ancova: A GLM Approach. 2011.

    Book  Google Scholar 

  20. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47:42–50.

    Article  CAS  PubMed  Google Scholar 

  21. Terawaki H, Yoshimura K, Hasegawa T, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988–93.

    Article  CAS  PubMed  Google Scholar 

  22. Singh K, Prasad KN, Mishra P, et al. Toll-like receptors TLR4 (Asp299Gly and Thr399Ile) and TLR2 (Arg677Trp and Arg753Gln) gene polymorphisms in end-stage renal disease patients on peritoneal dialysis. Int Urol Nephrol. 2015;47:2031–7.

    Article  CAS  PubMed  Google Scholar 

  23. Pahl MV, Gollapudi S, Sepassi L, et al. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010;25:205–12.

    Article  CAS  PubMed  Google Scholar 

  24. Ebrahimi M, Norouzi P, Aazami H, et al. Review on oxidative stress relation on COVID-19: Biomolecular and bioanalytical approach. Int J Biol Macromol. 2021;189:802–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004;24(4):354–65.

  26. Canaud B, Cristol J-P, Morena M, et al. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999;17:99–106.

    Article  CAS  PubMed  Google Scholar 

  27. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–26.

    Article  CAS  PubMed  Google Scholar 

  28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Xavier LL, Neves PFR, Paz LV, et al. Does Angiotensin II Peak in Response to SARS-CoV-2? Front Immunol. 2020;11: 577875.

    Article  CAS  PubMed  Google Scholar 

  30. Fang Y, Gao F, Liu Z. Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways. QJM. 2019;112:914–24.

    Article  CAS  PubMed  Google Scholar 

  31. Lopes RA, Neves KB, Tostes RC, et al. Downregulation of Nuclear Factor Erythroid 2-Related Factor and Associated Antioxidant Genes Contributes to Redox-Sensitive Vascular Dysfunction in Hypertension. Hypertension. 2015;66:1240–50.

    Article  CAS  PubMed  Google Scholar 

  32. Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc. 2010;5:51–66.

    Article  CAS  PubMed  Google Scholar 

  33. Abouhashem AS, Singh K, Azzazy HM, et al. Is low alveolar type II cell SOD3 in the lungs of elderly linked to the observed severity of COVID-19? 140 Huguenot Street, 3rd Floor New …,: In, Mary Ann Liebert, Inc., publishers; 2020.

    Google Scholar 

  34. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752–60.

    Article  CAS  PubMed  Google Scholar 

  35. Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9(11):1211.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Grajales-Reyes GE, Colonna M. Interferon responses in viral pneumonias. Science. 2020;369:626–7.

    Article  CAS  PubMed  Google Scholar 

  37. Adhikari NKJ, Hashmi M, Tirupakuzhi Vijayaraghavan BK, et al. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. JAMA. 2023;330:1745–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Laforge M, Elbim C, Frère C, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20:515–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sánchez-Rodríguez MA, Mendoza-Núñez VM. Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans. Oxid Med Cell Longev. 2019;2019:4128152.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank EONE Laboratories in Incheon, Korea, for the technical support of laboratory tests.

Funding

This work was supported by the Chung-Ang Jeil Hospital research fund in Chungbuk, South Korea (CAJ-2023-AS 01). Data analysis was supported by the Bio and Medical Technology Development Program of the National Research Foundation, funded by the Korean government (No. 2021M3E5E3081425).

Author information

Authors and Affiliations

  1. Department of Pediatrics, Chung-Ang Jeil Hospital, Chungbuk, South Korea

    Nam-Seon Beck

  2. Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, South Korea

    Yeonju Seo

  3. Department of Statistics, Seoul National University, Seoul, South Korea

    Taesung Park

  4. Department of Neurology, Chung-Ang Jeil Hospital, Chungbuk, South Korea

    Sang‑Sin Jun

  5. Department of Orthopedic Surgery, Chung-Ang Jeil Hospital, Chungbuk, South Korea

    Joung-Il Im

  6. Department of Nephrology, Chung-Ang Jeil Hospital, Chungbuk, South Korea

    Sae-Yong Hong

Authors
  1. Nam-Seon Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeonju Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taesung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sang‑Sin Jun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joung-Il Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sae-Yong Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NB: original draft preparation, review and editing. YS, TP: formal analysis. SJ: data curation, JL: supervision. SH: conceptualization, investigation.

Corresponding author

Correspondence to Sae-Yong Hong.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Public Institutional Review Board of the Ministry of Health and Welfare of South Korea (http://irb.or.kr/menu02/summary.aspx, approval no: P01-202308–01-030 on 2023.8.18). It was conducted using the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants involved in the study. The data presented in this study are available on request from the corresponding author (syhong0526@gmail.com).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beck, NS., Seo, Y., Park, T. et al. Oxidative stress in patients with coronavirus disease and end-stage renal disease: a pilot study. BMC Nephrol 25, 155 (2024). https://doi.org/10.1186/s12882-024-03584-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12882-024-03584-0

Keywords

BMC Nephrology

ISSN: 1471-2369

Contact us